Background: It is increasingly recognized that cancer progression induces systemic immune changes in the host. Alterations in number and function of immune cells have been identified in cancer patients' peripheral blood and lymphoid organs. Recently, we found dysregulated cytokine signaling in peripheral blood T cells from breast cancer (BC) patients, even those with localized disease. Methods: We used phosphoflow cytometry to determine the clinical significance of cytokine signaling responsiveness in peripheral blood monocytes from non-metastatic BC patients at diagnosis. We also examined the correlation between cytokine signaling in peripheral monocytes and the number of tumor-infiltrating macrophages in paired breast tumors. Findings: Our results show that cytokine (IFNg) signaling may also be dysregulated in peripheral blood monocytes at diagnosis, specifically in BC patients who later relapsed. Some patients exhibited concurrent cytokine signaling defects in monocytes and lymphocytes at diagnosis, which predict the risk of future relapse in two independent cohorts of BC patients. Moreover, IFNg signaling negatively correlates with expression of CSF1R on monocytes, thus modulating their ability to infiltrate into tumors. Interpretation: Our results demonstrate that tumor-induced systemic immune changes are evident in peripheral blood immune cells for both myeloid and lymphoid lineages, and point to cytokine signaling responsiveness as important biomarkers to evaluate the overall immune status of BC patients.
Introduction
Cancer progression can induce not only local intratumoral immune dysfunction, but also changes in lymphoid organs at distant sites [1À5]. These tumor-induced distant immune changes support the view that cancer is a systemic disease. Preserved systemic immune function is associated with better clinical outcome and response to immunotherapy [6] .
Macrophages play an important role in cancer development and progression [7À9] and peripheral blood monocytes are the major source of tumor-associated macrophages (TAMs) [10] . Infiltration by TAMs is associated with worse clinical outcome in breast cancer (BC) [11, 12] and many other cancer types [13] . IFNg is an important cytokine that plays a central role in monocyte differentiation and function. IFNg induces monocyte differentiation into immunostimulatory M1 phenotype and reverses the immunosuppressive functions of TAMs [14] . IFNg signals through the IFNgR1/IFNgR2 complex to activate signal transducer and activator of transcription (STAT) signaling [15] . Immune cell activation by IFNg is driven by phosphorylation of STAT1, which dimerizes and translocates into the nucleus to initiate transcription of interferon-stimulated genes (ISGs) [16] .
We previously found dysregulated signaling responses to several cytokines in peripheral blood T cells from BC patients, even those with localized tumors [17, 18] . However, whether changes in cytokine signaling responses extend beyond lymphocytes to myeloid cells remained unclear. Here, we sought to investigate cytokine signaling in peripheral blood monocytes from BC patients, focusing on the key pro-inflammatory cytokine IFNg. We analyzed IFNg signaling responsiveness between relapsed and relapse-free BC patients in peripheral monocytes from blood collected at diagnosis. We also correlated TAM infiltration in matched tumors from these patients in relation to IFNg signaling response in their peripheral blood monocytes.
Material and methods

Study design and cohorts
The study population of the discovery cohort consisted of 40 breast cancer patients from Stanford Medical Center and City of Hope Comprehensive Cancer Center. These patients were all diagnosed with breast cancer and had blood collected before June 2012. The validation cohort was composed of 78 breast cancer patients from City of Hope Comprehensive Cancer Center. These patients were diagnosed with breast cancer and had PBMCs collected after June 2012. We only analyzed blood samples collected at diagnosis before surgery or any systemic therapy from patients with clinical follow-up for more than 36 months. All patients in this study received standard of care treatments.
This study was approved by the Institutional Review Board of Stanford Medical Center and City of Hope Comprehensive Cancer Center. All patients had signed written informed consents.
Human samples
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by Ficoll-Paque density centrifugation and cryopreserved in 10% DMSO FBS. Age-matched healthy control peripheral blood samples were obtained from the City of Hope Blood Donor Center. Only PBMC samples with cell viability 85% after thawing were selected.
Phosphoflow cytometry after IFNg stimulation
Cryopreserved PBMCs were thawed and rested for 16 h. PBMCs were stimulated with IFNg (Peprotech, Rocky Hills, NJ, USA) at 50 ng/ ml at 37°C for 15 min followed by fixation with 1.5% paraformaldehyde (PFA) for 10 min at room temperature. Cells were washed with PBS to remove PFA, and permeabilized by the addition of 100% methanol.
Flow cytometry
The following antibodies were utilized: CD3 (UCHT1), CD4 (SK3), CD45RA (L48), CD8 (SK1), CD16 (3G8), CD33 (P67.6), pSTAT1 (pY701) (4a), total STAT1 (1/stat1), CXCR4 (12G5), IFNgR1(GIR208) (BD Biosciences, San Jose, CA, USA), CD14 (HCD14), CSF1R (94D21E4), CCR2 (K036C2), VEGFR2 (7D46), MRC1 (15-2), CD163 (GHI/61) (Biolegend, San Diego, CA, USA), LIVE/DEAD Fixable Blue Dead Cell Stain (Life Technologies, Carlsbad, CA, USA). The IFNg signaling response was expressed as the IFNg induced median fluorescence intensity (MFI) minus the unstimulated MFI of pSTAT1. Flow cytometry was performed using Fortessa Flow Cytometers (BD Biosciences). Flow cytometry data was analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA.).
Plasma IFNg ELISA
All patient plasma samples were collected prior to surgery or administration of any therapy. Plasma samples were kept frozen at À80°C then thawed shortly before determination of IFNg level. IFNg levels were determined by high sensitivity ELISA (eBioscience, San Diego, CA, USA) according to manufacturer's protocol.
Multiplex immunofluorescence staining and imaging
Formalin-fixed paraffin-embedded (FFPE) biopsies of untreated primary breast tumors tissues were cut into 3-um sections and affixed to microscope slides. They were deparaffinized with xylene and rehydrated with decreasing concentrations of ethanol in water. Heat-induced epitope/antigen retrieval was performed in EnVision Ò FLEX Target Retrieval Solution, High pH (pH 9) (K8004/5, Agilent, Santa Clara, CA, USA) or AR6 buffer (pH 6) (PerkinElmer, Hopkinton, MA, USA) using a microwave oven. Blocking was performed for 10 min using Antibody Diluent, Background Reducing (S3022, Agilent) to minimize non-specific background staining. Tissue slides were stained with the following primary antibodies for 1 h on a shaker at room temperature: CD68 (KP1), Cytokeratin (AE1/AE3) (Biocare) and then detected by a horseradish peroxidase (HRP)-conjugated secondary antibody followed Opal Ò fluorescence IHC Kit (PerkinElmer) at a 1:100 dilution following a 10 min incubation. To perform multicolor immunofluorescent staining, the slide would be serially stained with the microwave incubation acting to remove previous antibodies while simultaneously exposing the next epitope of interest. After staining the final marker, cell nuclei were stained with DAPI (PerkinElmer) and the slides were mounted with ProLong Gold Antifade Reagent (P36930, ThermoFisher, Waltham, MA, USA).
Whole tissue section imaging and quantitative analysis
Whole tissue section images were acquired at 200 £ magnification using the imaging system Vectra (PerkinElmer, Waltham, MA, USA) as previously described [19] and then images taken were analyzed using the image analysis software inForm
Research in context
Evidence before this study Cancer is a systemic disease. Primary tumor progression can induce distant changes on immune cells function, mobilization and differentiation within primary and secondary lymphoid organs, such as bone marrow, spleen and lymph node, well before clinically evident metastasis develops. Our previous findings show that cancer-induced systemic immune changes can be evident from altered cytokine signaling in peripheral blood lymphocytes from breast cancer patients.
Added value of the study
Concurrent with dysregulated cytokine signaling in peripheral blood lymphocytes, our results here show that tumor-induced systemic immune changes extend to peripheral blood monocytes. Altered signaling responses in peripheral monocytes correlate with clinical outcome, demonstrating that systemic immune changes persist in some patients after initial therapy and underlie future relapse.
Implications of all the available evidence
Concurrent development of altered signaling responses in peripheral blood monocytes and T cells further supports cancer as a systemic disease. Identifying and understanding additional tumor-induced systemic immune abnormalities will provide significant implications for future risk evaluation of cancer patients and therapeutic opportunities.
(PerkinElmer) to enumerate the total number of CD68 + cells per tissue section. The macrophage infiltration (CD68 + %) was expressed by dividing the cell number of CD68 + cells with the number of total cells of the tissue section.
Statistical analysis
MannÀWhitney tests were used to determine the statistical significance of BC patient with healthy donors (Graphpad Prism, Graph-Pad Software, LaJolla, CA, USA). Relapse-free survival (RFS) was defined as the time from the date of diagnosis of BC to the date of cancer recurrence or death. Kaplan-Meier method with log-rank test was used to determine IFNg signaling responsiveness as prognostic factors for RFS of BC patients. Multivariate Cox regression model analysis was performed to determine independence of prognostic factor. ROC analysis was used to evaluate the prognostic performance. All tests with p value<0.05 were considered statistically significant.
Results
Breast cancer induces concurrent cytokine signaling defects in peripheral blood monocytes and lymphocytes
To investigate breast cancer-induced systemic changes on cytokine signaling in peripheral blood monocytes, we analyzed IFNginduced phosphorylation of STAT1 (pSTAT1) in peripheral monocytes (CD33 + CD14 + CD3 À CD16 À/lo ) from BC patients with localized tumors via phosphoflow cytometry (gating strategy in Fig. S1a ). Only patients with blood collected at diagnosis before surgery or any systemic therapy and who later relapsed within 5 years were selected. IFNg signaling response (DMFI) is represented by IFNg stimulated minus unstimulated pSTAT1 medium fluorescence intensity (MFI) (Fig. 1a ). To examine whether tumor-induced systemic changes on IFNg signaling are evident in peripheral monocytes from BC patients at diagnosis who later relapsed, we compared the IFNg signaling responsiveness in peripheral monocytes between BC patients who later relapsed (n = 22) or remained relapse-free (n = 96), and agematched healthy donors (n = 27). IFNg-induced pSTAT1 in peripheral blood monocytes at diagnosis was significantly higher in relapse-free BC patients and in healthy donors as compared to BC patients who later relapsed (Fig. 1b ). The levels of IFNg receptor IFNgR1 were also significantly higher in monocytes from healthy donors than in relapsed BC patients ( Fig. 1c ). In contrast, levels of basal pSTAT1 (Fig. S1b) and total STAT1 (Fig. S1c ), and frequencies of monocyte ( Fig.  S1d) were similar between relapsed, relapse-free BC patients and healthy donors.
In addition, we found that IFNg signaling responsiveness in monocytes from BC patients whose blood were collected at relapse (n = 10) were significantly lower than in patients who achieved and remained in remission for at least 3 years after their most recent relapse (n = 10) ( Fig. S1e ), indicating that altered IFNg signaling responsiveness in peripheral monocytes may be reversible when patients achieve remission.
We previously found dysregulated cytokine signaling in peripheral blood T cells from BC patients at diagnosis (17, 18) . To investigate whether cytokine signaling in peripheral monocytes and T cells could be altered concurrently, we examined the correlation between IFNg signaling in monocytes and IL-6 signaling in CD4 + naïve T cells (IL-6 Phosphflow gating strategy in Fig. S2 ). Importantly, we found a significant positive correlation between IFNg-pSTAT1 in monocytes and IL-6-pSTAT1/3 in CD4 + naïve T cells (Fig. 1d) . Moreover, BC patients who later relapsed not only had lower IFNg signaling in monocytes and but also lower IL-6 signaling in T cells (Fig. 1e) . These results indicate that BC patients likely to relapse tend to have dysregulated cytokine signaling in peripheral blood myeloid cells and lymphocytes concurrently at diagnosis.
IFNg signaling in peripheral monocytes correlates with tumor infiltration of macrophages
Given that high TAMs infiltration associates with poor outcome in BC and peripheral monocytes are the major source of TAMs, we hypothesized that the IFNg signaling responsiveness in peripheral monocytes may influence tumor infiltration by macrophages. To test this hypothesis, we examined the IFNg signaling response in peripheral monocytes by flow cytometry and quantified the macrophage infiltration in paired primary breast tumors from the same patients (n = 20) via whole tissue section multispectral imaging ( Fig. 2a ). Tumor infiltration of macrophages (%CD68 + ) was quantified by dividing the number of TAMs (CD68 + ) by the total number of cells in the whole tissue section. Indeed, we found a significant negative association between IFNg signaling responsiveness in peripheral monocytes and degree of TAM infiltration in paired primary tumors ( Fig. 2b ), suggesting that patients who have lower IFNg signaling response in peripheral monocytes tend to have more tumor-infiltrating macrophages. Given that TAMs are recruited to tumors mainly through CSF1R and chemokine receptors CCR2, CXCR4 and VEGFR2 expressed on monocytes [14] , we next addressed whether IFNg signaling responsiveness correlates with levels of these chemokine receptors. Amongst these chemokine receptors, we found that IFNg signaling response negatively associated with levels of CSF1R ( Fig. 2c ) but not CXCR4, CCR2 or VEGFR2 (Fig. S3aÀc ). Moreover, we found a positive association between levels of CSF1R on peripheral monocytes and numbers of TAMs in paired primary tumors (Fig. 2d ), reflecting the importance of CSF1R in TAM recruitment. To determine whether IFNg negatively regulates expression of CSF1R, we treated peripheral blood monocytes from BC patients with IFNg at low concentration in vitro and found that IFNg downregulated the levels of CSF1R on monocytes in a dose-dependent manner ( Fig. 2e) . These findings demonstrate a link between IFNg signaling in peripheral blood monocytes and their potential to infiltrate into tumors.
IFNg signaling responsiveness in peripheral blood monocytes predicts RFS in BC patients
To investigate the clinical significance of IFNg signaling responsiveness in peripheral blood monocytes of BC patients, we used Kaplan-Meier survival analysis and log-rank test to determine the relationship between IFNg signaling responsiveness and relapse-free survival (RFS). Only patients with blood collected at diagnosis before surgery or any systemic therapy and who had been clinically followed for at least 36 months were selected (clinical and pathological characteristics are summarized in Table 1 ). The median follow-up time of BC patients (n = 40) was 63 months (range, 36À92 months). We compared RFS between BC patients with high vs. low IFNg signaling response, defined as patients with IFNg-induced pSTAT1 DMFI 25% quantile and < 25% quantile, respectively. Patients with low DMFI (n = 10) had significantly worse RFS (p = 0.001) than those with high DMFI (n = 30) ( Fig. 3a) , indicating that lower IFNg signaling response in peripheral blood monocytes at diagnosis correlates with worse RFS.
To evaluate the robustness of IFNg signaling responsiveness in predicting the risk of future relapse of BC, the clinical significance of IFNg signaling in peripheral monocytes was tested in an independent validation cohort of newly diagnosed BC patients (n = 78). Again, only patients with blood collected at diagnosis before surgery or any therapy and had been clinically followed for at least 36 months were selected (clinical and pathological characteristics are summarized in Table 1 ). The median follow-up time of BC patients of this cohort was 47 months (range, 36À59 months). Using the same IFNg-induced pSTAT1 DMFI cut-off derived from the discovery cohort (DMFI=4071), BC patients in the validation cohort were classified into high (n = 48) or low (n = 30) IFNg signaling response groups. As in the discovery cohort, Kaplan-Meier analysis showed that patients with low IFNg signaling response had significantly worse RFS (p = 0.0002) than those in the high IFNg signaling response group (Fig. 3b) .
In a multivariate analysis adjusted for clinicopathologic characteristics of BC patients (age, tumor stage, grade, nodal status and subtype), IFNg-induced pSTAT1 retained prognostic significance (p = 0.0007) for RFS (Table S1 ), suggesting that the IFNg signaling response in peripheral blood monocytes at diagnosis is a prognostic biomarker of clinical outcome independent of other clinicopathologic characteristics. Moreover, plasma IFNg levels were similar between relapse-free and relapsed BC patients (Fig. S4a) and we found no correlation between plasma IFNg level and IFNg signaling response in peripheral monocytes (Fig. S4b) .
The prognostic potential of IFNg signaling in peripheral monocytes to predict future relapse was also evaluated by receiver operating characteristic (ROC) analysis. IFNg signaling responsiveness (DMFI) achieved an area under the curve (AUC) of 0.81 (95% CI 0.72À0.91, p < 0.0001), with 82% sensitivity and 77% specificity to predict future relapse when we used the low and high IFNg signaling response cut-off (DMFI=4071) from the discovery and validation cohorts (Fig. 3c ).
Among the ER + HER2 À luminal BC patients, we examined whether IFNg signaling responsiveness in peripheral blood monocytes correlates with Oncotype DX scores of their paired primary tumors (n = 46). There is a trend of negative correlation between IFNg-pSTAT1 and Oncotype DX scores (r=À0.24, p = 0.1) ( Fig. S5a) . Interestingly, 6 out of 8 relapsed patients had Oncotype DX scores ( 15, indicating low risk of recurrence) -these 6 relapsed patients still had low IFNg signaling in peripheral monocytes (indicating high risk of recurrence) (Fig. S5b ). As such, cytokine signaling responsiveness in peripheral blood monocytes may provide additional prognostic information beyond Oncotype DX from tumor samples.
In addition, we also examined IFNg signaling response in nonclassical monocytes (CD16 hi CD14 À/lo ) ( Fig. S6a) and found that IFNginduced pSTAT1 were significantly higher in non-classical monocytes than in classical monocytes from BC patients (Fig. S6b ). However, IFNg signaling response in non-classical monocytes (Fig. S6c ) and frequency of non-classical monocytes (Fig. S6d) were similar between relapse-free and relapsed BC patients.
Since IFNg induces monocyte differentiation into immunostimulatory M1-like phenotype, we investigated whether IFNg signaling responsiveness negatively correlates with expression levels of M2like proteins, such as mannose receptor C-type 1 (MRC1/CD206) and CD163. We determined the levels of MRC1 and CD163 by flow cytometry and examined their correlations with IFNg-induced pSTAT1 in peripheral monocytes from BC patients (n = 12). There is a trend of negative correlation between IFNg-induced pSTAT1 and MRC1 (r=À0.36, p = 0.26) ( Fig. S7a ), but no correlation between IFNginduced pSTAT1 and CD163 (r=À0.19, p = 0.56) ( Fig. S7b ).
Discussion
Accumulating data support the view that cancer is a systemic disease. Tumors must induce systemic immunological changes in peripheral blood and distant lymphoid organs to facilitate cancer progression and metastasis. Concurrent with dysregulated cytokine signaling in peripheral blood lymphocytes [17, 18] , here we show that tumor-induced systemic immune changes extend to peripheral blood monocytes.
TAMs are the dominant infiltrating immune cells in many human tumors and can represent up to 50% of the tumor mass [20] . As the major source of TAMs [21, 22] , peripheral blood monocytes are recruited to tumors via various tumor-derived chemokines and motility factors such as CSF1 [23] . Inhibition of IFNg and up-regulation of CSF1 have been shown to promote the conversion of monocytes into immunosuppressive macrophages that inhibit T cellmediated responses [24] . Since the CSF1-CSF1R axis is important in monocytes recruitment, blockade of CSF1R has been used to prevent tumor metastasis and progression [25À27]. Our finding that IFNg signaling response negatively associated with the levels of CSF1R extends beyond previous reports that IFNg suppresses the expression of CSF1R in macrophage [28] , and reveals a novel mechanism behind the correlation between IFNg signaling response with clinical outcome. Since CSF1R expression is known to be negatively regulated by IFNg, our finding of higher levels of CSF1R in peripheral blood monocytes with lower IFNg signaling responsiveness is consistent with these previous findings. Furthermore, our finding that relapsed BC patients tend to have normal plasma levels of IFNg at diagnosis demonstrates that cancer-induced systemic immune changes may not necessarily be mediated through elevated/altered cytokine levels in circulation, but in the ability of immune cells to respond to cytokines. Altered IFNg signaling responsiveness was not due to basal STAT1 levels, but differences in IFNg-induced STAT1 phosphorylation. These results suggest altered priming of peripheral blood monocytes in relapse-free vs. relapsed patients.
Concurrent development of altered signaling responses in peripheral blood monocytes and T cells further supports cancer as a systemic disease. T cells may traffic through tumors and tumor-draining lymph nodes (TDLNs) leading to their altered function [29, 30] . However, monocytes remain within tissues once they leave the blood [31] . Thus, signaling alterations in peripheral blood monocytes must have developed at their origin, from cancer-induced distant effects within bone marrow and/or spleen. Indeed, it has been shown that cancer can induce distant changes on myeloid cells function, mobilization and differentiation within bone marrow [32À35] and spleen [36À39], well before clinically evident metastasis develops. Importantly, these altered signaling responses correlate with clinical outcome, demonstrating that systemic immune changes persist in some patients after initial therapy and underlie future relapse. Identifying and understanding additional tumorinduced systemic immune abnormalities will provide significant implications for future risk evaluation of cancer patients and therapeutic opportunities. Fig. 3 . IFNg signaling responsiveness in peripheral monocytes at diagnosis predicts future relapse of breast cancer. PBMCs from breast cancer patients (BC) were stimulated with IFNg at 50 ng/ml for 15 min. IFNg signaling response (DMFI) in peripheral monocytes is determined by IFNg stimulated MFI minus unstimulated MFI of pSTAT1. (a) Relapse-free survival (RFS) was compared between BC patients of discovery cohort (n = 40) with low and high IFNg signaling response using Kaplan-Meier estimate and log rank test (p = 0.001). The 25% quantile of IFNg-induced pSTAT1 (DMFI) was used as the cut-off (DMFI=4071) to divide BC patients into low and high IFNg response groups. (b) BC patients of validation cohort (n = 78) were divide into low and high IFNg response groups using the cut-off (DMFI=4071) from the discovery cohort. RFS was compared between BC patients with low and high IFNg signaling response using Kaplan-Meier estimate and log rank test (p = 0.0002). (c) Receiver operating characteristic (ROC) analysis for prognostic potential of IFNg signaling response (DMFI) in peripheral monocytes from BC patients at diagnosis (n = 118). All the blood were collected at diagnosis prior to surgery or any systemic therapy from BC patients who had been clinically followed for at least 36 months. These are the same BC patients analyzed in Fig. 1 .
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